<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lifetime cancer risk related to Lynch genotypes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lifetime cancer risk related to Lynch genotypes</h1>
<div class="graphic"><div class="figure"><div class="ttl">Lifetime cancer risk related to Lynch genotypes</div><div class="cntnt"><table cellspacing="0"><colgroup width="16%"></colgroup><colgroup span="12" width="7%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Cancer site</td> <td class="subtitle1" colspan="3">MLH1</td> <td class="subtitle1" colspan="3">MSH2<sup>Δ</sup></td> <td class="subtitle1" colspan="3">MSH6</td> <td class="subtitle1" colspan="3">PMS2</td> </tr> <tr> <td class="subtitle2">Female</td> <td class="subtitle2">Male</td> <td class="subtitle2">Both</td> <td class="subtitle2">Female</td> <td class="subtitle2">Male</td> <td class="subtitle2">Both</td> <td class="subtitle2">Female</td> <td class="subtitle2">Male</td> <td class="subtitle2">Both</td> <td class="subtitle2">Female</td> <td class="subtitle2">Male</td> <td class="subtitle2">Both</td> </tr> <tr class="divider_bottom"> <td><strong>Any Lynch cancer</strong></td> <td class="centered"><strong>71 to 81%</strong></td> <td class="centered"><strong>71 to 72%</strong></td> <td class="centered"><strong>71 to 90%</strong></td> <td class="centered"><strong>61 to 84%</strong></td> <td class="centered"><strong>52 to 75%</strong></td> <td class="centered"><strong>52 to 84%</strong></td> <td class="centered"><strong>62 to 65%</strong></td> <td class="centered"><strong>41 to 47%</strong></td> <td class="centered"><strong>58 to 73%</strong></td> <td class="centered"><strong>–</strong></td> <td class="centered"><strong>–</strong></td> <td class="centered"><strong>34 to 52%</strong></td> </tr> <tr class="divider_bottom"> <td>Colorectal</td> <td class="centered">35 to 57%</td> <td class="centered">39 to 78%</td> <td class="centered">35 to 90%</td> <td class="centered">26 to 68%</td> <td class="centered">31 to 63%</td> <td class="centered">52 to 84%</td> <td class="centered">20 to 30%</td> <td class="centered">12 to 69%</td> <td class="centered">18 to 58%</td> <td class="centered">12 to 15%</td> <td class="centered">13 to 20%</td> <td class="centered">12 to 52%</td> </tr> <tr class="divider_bottom"> <td>Endometrial</td> <td class="centered">20 to 57%</td> <td class="centered">–</td> <td class="centered">–</td> <td class="centered">21 to 71%</td> <td class="centered">–</td> <td class="centered">–</td> <td class="centered">17 to 71%</td> <td class="centered">–</td> <td class="centered">–</td> <td class="centered">13 to 15%</td> <td class="centered">–</td> <td class="centered">–</td> </tr> <tr class="divider_bottom"> <td>Gastric</td> <td class="centered">3 to 15%</td> <td class="centered">6 to 37%</td> <td class="centered">Up to 37%</td> <td class="centered">13 to 19%</td> <td class="centered">5 to 20%</td> <td class="centered">Up to 20%</td> <td class="centered">1 to 4%</td> <td class="centered">1 to 8%</td> <td class="centered">Up to 8%</td> <td class="centered">–</td> <td class="centered">–</td> <td class="centered">Unknown*</td> </tr> <tr class="divider_bottom"> <td>Ovarian</td> <td class="centered">8 to 20%</td> <td class="centered">–</td> <td class="centered">–</td> <td class="centered">12 to 38%</td> <td class="centered">–</td> <td class="centered">–</td> <td class="centered">1 to 11%</td> <td class="centered">–</td> <td class="centered">–</td> <td class="centered">3 to 5%</td> <td class="centered">–</td> <td class="centered">–</td> </tr> <tr class="divider_bottom"> <td>Ureter/kidney</td> <td class="centered">2 to 5%</td> <td class="centered">4 to 5%</td> <td class="centered">Up to 5%</td> <td class="centered">6 to 19%</td> <td class="centered">6 to 18%</td> <td class="centered">Up to 19%</td> <td class="centered">1 to 5%</td> <td class="centered">1 to 2%</td> <td class="centered">Up to 5%</td> <td class="centered">–</td> <td class="centered">–</td> <td class="centered">Up to 4%</td> </tr> <tr class="divider_bottom"> <td>Bladder</td> <td class="centered">1 to 5%</td> <td class="centered">4 to 11%</td> <td class="centered">Up to 11%</td> <td class="centered">3 to 8%</td> <td class="centered">4 to 13%</td> <td class="centered">Up to 13%</td> <td class="centered">1 to 2%</td> <td class="centered">1 to 8%</td> <td class="centered">Up to 8%</td> <td class="centered">–</td> <td class="centered">–</td> <td class="centered">Unknown*</td> </tr> <tr class="divider_bottom"> <td>Prostate</td> <td class="centered" colspan="3">9 to 14%</td> <td class="centered" colspan="3">24 to 30%</td> <td class="centered" colspan="3">9 to 30%</td> <td class="centered" colspan="3">Up to 5%</td> </tr> <tr class="divider_bottom"> <td>Breast<sup>¶</sup></td> <td class="centered" colspan="3">Up to 19%</td> <td class="centered" colspan="3">Up to 16%</td> <td class="centered" colspan="3">Up to 14%</td> <td class="centered" colspan="3">Up to 15%</td> </tr> <tr class="divider_bottom"> <td>Brain</td> <td class="centered" colspan="3">Up to 2%</td> <td class="centered" colspan="3">Up to 8%</td> <td class="centered" colspan="3">Up to 4%</td> <td class="centered" colspan="3">–</td> </tr> <tr class="divider_bottom"> <td>Small bowel</td> <td class="centered" colspan="3">Up to 4%</td> <td class="centered" colspan="3">Up to 8%</td> <td class="centered" colspan="3">Up to 4%</td> <td class="centered" colspan="3">Unknown*</td> </tr> <tr class="divider_bottom"> <td>Pancreatobiliary</td> <td class="centered" colspan="3">Up to 5%</td> <td class="centered" colspan="3">Up to 5%</td> <td class="centered" colspan="3">Unknown*</td> <td class="centered" colspan="3">Unknown*</td> </tr> <tr> <td>Skin</td> <td class="centered" colspan="3">Up to 4%</td> <td class="centered" colspan="3">Up to 10%</td> <td class="centered" colspan="3">Up to 4%</td> <td class="centered" colspan="3">Unknown*</td> </tr> </tbody></table></div><div class="graphic_footnotes">* Data are insufficient to make a determination.<br/>¶ There is ongoing debate as to whether breast cancer is a Lynch syndrome associated cancer.<br/>Δ Cancer risks in individuals with a pathogenic <em>EPCAM</em> variant are similar to those with a pathogenic <em>MSH2 </em>variant.</div><div class="graphic_reference">Data from: 

<ol>
<li>Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305:2304.</li>
<li>Dowty JG, Win AK, Buchanan DD, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 2013; 34:490.</li>
<li>Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123:444.</li>
<li>Joost P, Therkildsen C, Dominguez-Valentin M, et al. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology 2015; 86:1212.</li>
<li>van der Post RS, Kiemeney LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010; 47:464.</li>
<li>Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med 2020; 22:15.</li>
<li>Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008; 135:419.</li>
<li>Ten Broeke SW, van der Klift HM, Tops CMJ, et al. Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol 2018; 36:2961.</li>
<li>Ryan NAJ, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies. JAMA Oncol 2017; 3:1702.</li>
<li>Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010; 102:193.</li>
<li>Choi YH, Cotterchio M, McKeown-Eyssen G, et al. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract 2009; 7:14.</li>
<li>Capelle LG, Van Grieken NC, Lingsma HF, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010; 138:487.</li>
<li>Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012; 30:4409.</li>
<li>Ramsoekh D, Wagner A, van Leerdam ME, et al. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hered Cancer Clin Pract 2009; 7:17.</li>
<li>Harkness EF, Barrow E, Newton K, et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: A cohort study. J Med Genet 2015; 52:553.</li></ol></div><div id="graphicVersion">Graphic 52285 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
